Cleave Biosciences Inc. is developing small molecules against new targets that regulate protein homeostasis. The compounds could offer better bioavailability than existing proteasome inhibitors and work in a wider range of cancers, including solid tumors.

The company is banking on assays and chemical matter in-licensed from scientific co-founders including Raymond Deshaies, a California Institute of Technology professor of biology and Howard Hughes Medical Institute investigator who co-founded proteasome inhibitor cancer company Proteolix Inc.